Format

Send to

Choose Destination
See comment in PubMed Commons below
Health Policy Plan. 2014 Jul;29(4):517-27. doi: 10.1093/heapol/czt041. Epub 2013 Jun 18.

Access to subsidized ACT and malaria treatment--evidence from the first year of the AMFm program in six districts in Uganda.

Author information

1
Harvard School of Public Health, Department of Global Health and Population, 665 Huntington Avenue, Boston, MA 02115, USA, Department of Economics, Northeastern University, 360 Huntington Avenue, 301 Lake Hall, Boston, MA 02115-5000, USA, The Brookings Institution, 1775 Massachusetts Ave, NW, Washington, DC 20036 and Harvard School of Public Health and Brookings Institution gfink@hsph.harvard.edu.
2
Harvard School of Public Health, Department of Global Health and Population, 665 Huntington Avenue, Boston, MA 02115, USA, Department of Economics, Northeastern University, 360 Huntington Avenue, 301 Lake Hall, Boston, MA 02115-5000, USA, The Brookings Institution, 1775 Massachusetts Ave, NW, Washington, DC 20036 and Harvard School of Public Health and Brookings Institution.

Abstract

OBJECTIVE:

To determine the effect of the Affordable Medicines Facility for malaria (AMFm) launched in April 2011 in Uganda on the use of Artemisinin Combination Therapies (ACTs) for malaria treatment.

METHODS:

2398 households across six districts in Eastern Uganda were monitored through monthly survey visits from April 2011 to April 2012. During each visit, health seeking modules were completed for any morbidity episode reported by the household. Additional surveys were conducted with 114 licensed drug shops in the same districts in April 2011 and April 2012. Changes in drug shops' stocking and pricing of ACTs, as well as changes in households' treatment behaviour and drug usage were analysed.

RESULTS:

The fraction of licensed drug shops reporting that an ACT was one of their top five bestselling antimalarial drugs increased from 32% to 84% (Δ=0.517, 95% Confidence Intervals (CI) [0.407, 0.628], P<0.001). The fraction of children under the age of 5 with fevers getting an ACT increased from 37% to 47% (Δ=0.103, 95% CI [0.070, 0.136], P<0.001), and the fraction of ACT treatments among patients getting any antimalarial increased from 51% to 65% (Δ=0.145, 95% CI [0.121, 0.169], P<0.001). The observed changes were particularly large among poorer households, and were smallest for households from the highest wealth quintile.

CONCLUSIONS:

The study results suggest that, during its first year of implementation in Uganda, the AMFm achieved its main objective of increasing the availability and use of ACTs. Estimates of the impact of the AMFm on ACT use for children under 5 imply that the program should be considered highly cost-effective under current World Health Organization (WHO) guidelines. The overall results look promising, but larger and longer term studies will be needed to assess the health impact and cost-effectiveness of the program.

KEYWORDS:

ACT; AMFm; Malaria; subsidies

PMID:
23783833
DOI:
10.1093/heapol/czt041
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center